Cargando…

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells

One of the most significant therapeutic challenges in the treatment of ovarian cancer is the development of recurrent platinum-resistant disease. Cancer stem cells (CSCs) are postulated to contribute to recurrent and platinum-resistant ovarian cancer (OvCa). Drugs that selectively target CSCs may au...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellio, Chiara, DiGloria, Celeste, Spriggs, David R., Foster, Rosemary, Growdon, Whitfield B., Rueda, Bo R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896080/ https://www.ncbi.nlm.nih.gov/pubmed/31671803 http://dx.doi.org/10.3390/cancers11111678

Ejemplares similares

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism
por: Kumstel, Simone, et al.
Publicado: (2022)

Notch signaling in serous ovarian cancer
por: Groeneweg, Jolijn W, et al.
Publicado: (2014)

Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy
por: Khan, Husain Yar, et al.
Publicado: (2022)

Smart Design of Mitochondria-Targeted and ROS-Responsive CPI-613 Delivery Nanoplatform for Bioenergetic Pancreatic Cancer Therapy
por: Zhang, Yi-Mei, et al.
Publicado: (2021)

CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling
por: Gao, Lixia, et al.
Publicado: (2020)

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer
por: Lang, Liwei, et al.
Publicado: (2021)

Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau
por: Starbuck, Kristen, et al.
Publicado: (2018)

A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer
por: Alistar, Angela, et al.
Publicado: (2017)

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
por: Lycan, Thomas W., et al.
Publicado: (2016)

Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
por: Egawa, Yuki, et al.
Publicado: (2018)

Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts
por: Mordhorst, Bethany R., et al.
Publicado: (2019)

Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613
por: Guardado Rivas, Moises O., et al.
Publicado: (2022)

CPI Hard Disk System
Publicado: (2017)

Scotch 777 6250 CPI
Publicado: (2017)

Synthesis of 6,13-difluoropentacene
por: Tripp, Matthias W, et al.
Publicado: (2020)

Galectins and Ovarian Cancer
por: Shimada, Chisa, et al.
Publicado: (2020)

The clinical significance of cytoplasmic inclusions(CPI) in synovial fluid examination.
por: Park, J., et al.
Publicado: (1996)

Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model
por: McCann, Christopher K., et al.
Publicado: (2011)

The Effect of Galangin on the Regulation of Vascular Contractility via the Holoenzyme Reactivation Suppressing ROCK/CPI-17 rather than PKC/CPI-17
por: Yoon, Hyuk-Jun, et al.
Publicado: (2022)

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
por: Wong, C, et al.
Publicado: (2014)

3M No. 700 Black Watch 6250 CPI
Publicado: (2017)

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
por: Gallay, Philippe A., et al.
Publicado: (2015)

Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
por: Hanna, Glenn J., et al.
Publicado: (2020)

MON-613 Lipid Abnormalities In Thyroid Dysfunction.
por: Franco, Luiz Fernando
Publicado: (2019)

The Long Intergenic Noncoding RNA 00707 Sponges MicroRNA-613 (miR-613) to Promote Proliferation and Invasion of Gliomas
por: Liu, Handong, et al.
Publicado: (2020)

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
por: Siegel, Matthew B., et al.
Publicado: (2015)

Immunoprofiling of T cell responses in melanoma patients undergoing CPI therapy
por: Talarico, Lee Ann, et al.
Publicado: (2015)

CPI motif interaction is necessary for capping protein function in cells
por: Edwards, Marc, et al.
Publicado: (2015)

Characterization of Species-Specific Repeats in 613 Prokaryotic Species
por: Koressaar, Triinu, et al.
Publicado: (2012)

Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses
por: Wang, Ying, et al.
Publicado: (2019)

Dynamics and Endocytosis of Flot1 in Arabidopsis Require CPI1 Function
por: Cao, Yangyang, et al.
Publicado: (2020)

MCN-CPI: Multiscale Convolutional Network for Compound–Protein Interaction Prediction
por: Wang, Shuang, et al.
Publicado: (2021)

Long Noncoding RNA LINC00460 Facilitates Colorectal Cancer Progression by Negatively Regulating miR-613
por: Wang, Lei, et al.
Publicado: (2020)

miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A
por: Liu, Cuiping, et al.
Publicado: (2020)

Radiation recall dermatitis during treatment of endometrial cancer with pembrolizumab plus lenvatinib: A case report
por: Heisler, Elise, et al.
Publicado: (2023)

Actin capping protein regulates postsynaptic spine development through CPI-motif interactions
por: Myers, Kenneth R., et al.
Publicado: (2022)

FRI613 Sex Differences In Human Islet Transcriptional Responses To Inflammation
por: Webster, Kierstin L, et al.
Publicado: (2023)

The Onchocerca volvulus Cysteine Proteinase Inhibitor, Ov-CPI-2, Is a Target of Protective Antibody Response That Increases with Age
por: Cho-Ngwa, Fidelis, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_0sffj9vhsgiemkpn0b431r6oe0